Australia’s Pharma Industry Urges No Cuts In PBS Spending
This article was originally published in PharmAsia News
Executive Summary
The head of Medicines Australia, which represents the pharmaceutical industry, urged the government to keep funding for the Pharmaceutical Benefits Scheme as it is, at $7 billion a year. Will Delaat, a cancer survivor, made the appeal as the government considers making budget cuts in the face of a faltering economy. Delaat said the government should quantify the areas of health spending before deciding which health programs to cut. Until the government has that information, he said, "don't jeopardize the integrity of the PBS." (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.